Recent Updates
Recently added Catalysts
CHE

David P. William s (513) 762-6901   Chemed Reports Fourth-Quarter 2019 Results   CINCINNATI

Key Takeaway: CONTACT: David P. Williams Chemed Reports Fourth-Quarter 2019 Results CINCINNATI, February 18, 2020 Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nati

Full Press Release Details

CONTACT: David P. Williams
Chemed Reports Fourth-Quarter 2019 Results
CINCINNATI, February 18, 2020 Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2019, versus the comparable prior-year period, as follows:
Consolidated operating results:
VITAS segment operating results:
Roto-Rooter segment operating results:
VITAS net revenue was $340 million in the fourth quarter of 2019, which is an increase of 10.7%, when compared to the prior-year period. This revenue increase is comprised primarily of a geographically weighted average Medicare reimbursement rate increase of approximately 5.5%, a 6.1% increase in days-of-care and an increase in the Medicare Cap billing limitation that decreased revenue 0.3%. This growth was partially offset by acuity mix shift, fluctuations in net room and board and contractual adjustments, the combination of which negatively impacted revenue growth approximately 0.7%, when compared to the prior-year period.
In the fourth quarter of 2019, VITAS accrued $4.5 million in Medicare Cap billing limitations. This compares to the prior-year Medicare Cap billing limitation of $3.5 million.
VITAS currently has 30 Medicare provider numbers. On a 12-month trailing basis, 23 of these provider numbers have a Medicare Cap cushion of 10% or greater, three provider numbers have a cap cushion between 0% and 5%, and four provider numbers are forecasted to have a Medicare Cap billing limitation.
Average revenue per patient per day in the fourth quarter of 2019 was $198.48, which is 5.0% above the prior-year period. Reimbursement for routine home care and high acuity care averaged $164.62 and $996.82, respectively. During the quarter, high acuity days-of-care were 4.1% of total days of care, 11-basis points less than the prior-year quarter. This 11-basis point mix shift in high acuity days-of-care reduced the increase in average revenue per patient per day from 5.5% to 5.0% in the quarter.
The fourth quarter 2019 gross margin, excluding Medicare Cap, was 26.3%, which is a 204-basis point margin improvement when compared to the fourth quarter of 2018.
Selling, general and administrative expense was $21.2 million in the fourth quarter of 2019, which is an increase of 3.9% compared to the prior-year quarter. Adjusted EBITDA, excluding Medicare Cap, totaled $70.5 million in the quarter, an increase of 27.0%. Adjusted EBITDA margin, excluding Medicare Cap, was 20.5% in the quarter, which is a 259-basis point margin improvement when compared to the prior-year period.
Roto-Rooter generated quarterly revenue of $182 million for the fourth quarter of 2019, an increase of $31.9 million, or 21.2%, over the prior-year quarter. On a unit for unit basis, which excludes the Oakland and HSW acquisitions completed in July and September 2019, respectively, Roto-Rooter generated quarterly revenue of $162 million for the fourth quarter of 2019, an increase of 7.9%, over the prior-year quarter.
Including acquisitions, total commercial revenue increased 26.4%. This aggregate commercial revenue growth consisted of drain cleaning revenue expanding 34.9%, commercial plumbing and excavation increasing 25.2%, and commercial water restoration declining 8.8%.
Excluding acquisitions, commercial drain cleaning revenue increased 7.1%, commercial plumbing and excavation declined 0.1%, and commercial water restoration declined 17.4%. Commercial water restoration represents approximately 10% of total water restoration service revenue. Overall, commercial revenue excluding acquisitions increased 1.2%.
Including acquisitions, total residential revenue increased 19.4%. This aggregate residential revenue growth consisted of residential drain cleaning increasing 25.5%, plumbing and excavation expanding 18.1%, and residential water restoration increasing 16.3%.
Excluding acquisitions, residential drain cleaning increased 10.1%, plumbing and excavation increased 7.4%, and residential water restoration increased 14.6%. Overall, residential sales excluding acquisitions increased 9.5%.
Roto-Rooter's gross margin in the quarter was 48.6%, a 15-basis point decline when compared to the fourth quarter of 2018. Adjusted EBITDA in the fourth quarter of 2019 totaled $43.7 million, an increase of 20.9%. The Adjusted EBITDA margin in the quarter was 24.0% which is equivalent to the prior year.
As of December 31, 2019, Chemed had total cash and cash equivalents of $6.2 million and long-term debt of $90 million.
In June 2018, Chemed entered into a five-year Amended and Restated Credit Agreement that consists of a $450 million revolving credit facility. The interest rate on this facility has a floating rate that is currently LIBOR plus 100-basis points. At December 31, 2019, the Company had approximately $322 million of undrawn borrowing capacity under this credit agreement.
During the quarter, the Company repurchased 50,000 shares of Chemed stock for $20.7 million which equates to a cost per share of $414.11. As of December 31, 2019, there was approximately $104 million of remaining share repurchase authorization under this plan.
Chemed restarted its share repurchase program in 2007. Since that time Chemed has repurchased over 14.1 million shares, aggregating approximately $1.2 billion at an average share cost of $85.93. Including dividends over this period, Chemed has returned approximately $1.4 billion to shareholders.
Revenue growth for VITAS in 2020, prior to Medicare Cap, is estimated to be in the range of 8.5% to 9.5%. Admissions and Average Daily Census in 2020 are estimated to expand approximately 3.5% to 4.5%. High acuity days-of-care are estimated at 4.1% of total 2020 days-of-care. Full-year Adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 18.7% to 19.0%. We are currently estimating $18 million for Medicare Cap billing limitations for calendar year 2020.
Roto-Rooter is forecasted to achieve full-year 2020 revenue growth of 13.0% to 14.0%. This revenue estimate is based upon unit for unit revenue growth of 4.0% to 5.0% in core plumbing and drain cleaning services, continued but slowing revenue growth from water restoration services, combined with 12-months of revenue in the Oakland and HSW acquisitions. Roto-Rooter's Adjusted EBITDA margin for 2020 is estimated to be in the range of 23.0% to 23.5%.
Based upon the above, full-year 2020 adjusted earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock options, costs related to litigation, intangible amortization of reacquired franchise rights and other discrete items, is estimated to be in the range of $16.20 to $16.50. This 2020 guidance assumes an effective corporate tax rate of 25.2%. Chemed's 2019 reported adjusted earnings per diluted share was $13.96.
Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, February 19, 2020, to discuss the Company's quarterly results and to provide an update on its business. The dial-in number for the conference call is (844) 743-2500 for U.S. and Canadian participants and +1 (661) 378-9533 for international participants. The Conference ID is 4939797. A live webcast of the call can be accessed on Chemed's website at www.chemed.com by clicking on Investor Relations Home.
A taped replay of the conference call will be available beginning approximately 24 hours after the call's conclusion. It can be accessed by dialing (855) 859-2056 for U.S. and Canadian callers and +1 (404) 537-3406 for international callers and will be available for one week following the live call. The replay Conference ID is 4939797. An archived webcast will also be available at www.chemed.com.
Chemed Corporation operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to approximately 19,000 patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.
Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing, drain cleaning, and water cleanup services through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in the republics of Indonesia and Singapore, and the Philippines.
This press release contains information about Chemed's EBITDA, Adjusted EBITDA and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed's financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company's operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed's management similarly uses EBITDA, Adjusted EBITDA and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed's management to estimate the resources required to meet Chemed's future financial obligations and expenditures. Chemed's EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed's net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.
Forward-Looking Statements
Certain statements contained in this press release and the accompanying tables are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "hope," "anticipate," "plan" and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These statements are based on current expectations and assumptions and involve various risks and uncertainties, which could cause Chemed's actual results to differ from those expressed in such forward-looking statements.
These risks and uncertainties arise from, among other things, possible changes in regulations governing the hospice care or plumbing and drain cleaning industries; periodic changes in reimbursement levels and procedures under Medicare and Medicaid programs; difficulties predicting patient length of stay and estimating potential Medicare reimbursement obligations; challenges inherent in Chemed's growth strategy; the current shortage of qualified nurses, other healthcare professionals and licensed plumbing and drain cleaning technicians; Chemed's dependence on patient referral sources; and other factors detailed under the caption "Description of Business by Segment" or "Risk Factors" in Chemed's most recent report on form 10-Q or 10-K and its other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on such forward-looking statements and there are no assurances that the matters contained in such statements will be achieved.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)(unaudited)
Three Months Ended December 31, For the Years Ended December 31,
2019 2018 2019 2018
Service revenues and sales 522,324 $ 457,507 $ 1,938,555 $ 1,782,648
Cost of services provided and goods sold 347,355 312,054 1,321,126 1,227,644
Selling, general and administrative expenses (aa) 83,291 66,735 305,712 271,209
Depreciation 11,126 9,822 40,870 38,464
Amortization 2,969 303 4,335 399
Other operating expenses 131 1,212 9,132 1,300
Total costs and expenses 444,872 390,126 1,681,175 1,539,016
Income from operations 77,452 67,381 257,380 243,632
Interest expense (1,133) (1,177) (4,535) (4,990)
Other income--net (bb) 3,276 (3,398) 8,764 958
Income before income taxes 79,595 62,806 261,609 239,600
Income taxes (14,015) (8,478) (41,686) (34,056)
Net income $ 65,580 $ 54,328 $ 219,923 $ 205,544
Earnings Per Share
Net income $ 4.09 $ 3.39 $ 13.77 $ 12.80
Average number of shares outstanding 16,022 16,026 15,969 16,059
Diluted Earnings Per Share
Net income $ 3.96 $ 3.26 $ 13.31 $ 12.23
Average number of shares outstanding 16,565 16,670 16,527 16,803
(aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands):
Three Months Ended December 31, For the Years Ended December 31,
2019 2018 2019 2018
SG&A expenses before long-term incentive compensation
and the impact of market value adjustments related to
deferred compensation plans $ 77,053 $ 68,034 $ 289,828 $ 264,304
Market value adjustments related to deferred
compensation trusts 3,160 (3,541) 8,254 287
Long-term incentive compensation 3,078 2,242 7,630 6,618
Total SG&A expenses $ 83,291 $ 66,735 $ 305,712 $ 271,209
(bb) Other income--net comprises (in thousands):
Three Months Ended December 31, For the Years Ended December 31,
2019 2018 2019 2018
Market value adjustments related to deferred
compensation trusts $ 3,160 $ (3,541) $ 8,254 $ 287
Interest income 126 143 513 671
Other (10) - (3) -
Total other income--net $ 3,276 $ (3,398) $ 8,764 $ 958
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)(unaudited)
December 31,
2019 2018
Assets
Current assets
Cash and cash equivalents $ 6,158 $ 4,831
Accounts receivable less allowances 143,827 119,504
Inventories 7,462 5,705
Prepaid income taxes 10,074 10,646
Prepaid expenses 23,150 19,154
Total current assets 190,671 159,840
Investments of deferred compensation plans held in trust 77,446 65,624
Properties and equipment, at cost less accumulated depreciation 175,763 162,033
Lease right of use asset 111,652 -
Identifiable intangible assets less accumulated amortization 126,370 68,253
Goodwill 577,367 510,570
Other assets 9,048 9,209
Total Assets $ 1,268,317 $ 975,529
Liabilities
Current liabilities
Accounts payable $ 51,101 $ 50,150
Accrued insurance 50,328 46,095
Accrued compensation 70,814 63,329
Accrued legal 6,941 1,857
Short-term lease liability 39,280 -
Other current liabilities 43,756 30,239
Total current liabilities 262,220 191,670
Deferred income taxes 18,504 21,598
Long-term debt 90,000 89,200
Deferred compensation liabilities 76,446 64,616
Long-term lease liability 86,656 -
Other liabilities 7,883 17,111
Total Liabilities 541,709 384,195
Stockholders' Equity
Capital stock 35,811 35,311
Paid-in capital 860,671 774,358
Retained earnings 1,425,752 1,225,617
Treasury stock, at cost (1,597,940) (1,446,296)
Deferred compensation payable in Company stock 2,314 2,344
Total Stockholders' Equity 726,608 591,334
Total Liabilities and Stockholders' Equity $ 1,268,317 $ 975,529
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)(unaudited)
For the Years Ended December 31,
2019 2018
Cash Flows from Operating Activities
Net income $ 219,923 $ 205,544
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization 45,205 38,863
Stock option expense 14,831 12,611
Litigation settlement 6,000 -
Noncash long-term incentive compensation 5,740 5,405
(Benefit)/provision for deferred income taxes (2,770) 5,187
Loss on sale of transportation equipment 2,266 -
Noncash directors' compensation 767 766
Amortization of debt issuance costs 306 441
Amortization of restricted stock awards - 446
Changes in operating assets and liabilities, excluding
amounts acquired in business combinations:
Increase in accounts receivable (19,247) (5,570)
Increase in inventories (1,757) (351)
Increase in prepaid expenses (3,491) (2,665)
Increase in accounts payable and
other current liabilities 28,417 8,935
Change in current income taxes 161 18,898
Net change in lease assets and liabilities 3,108 -
Increase in other assets (11,963) (5,544)
Increase in other liabilities 12,354 3,451
Other sources 1,399 721
Net cash provided by operating activities 301,249 287,138
Cash Flows from Investing Activities
Business combinations, net of cash acquired (138,010) (53,177)
Capital expenditures (53,022) (52,872)
Other sources 272 824
Net cash used by investing activities (190,760) (105,225)
Cash Flows from Financing Activities
Proceeds from revolving line of credit 482,900 469,550
Payments on revolving line of credit (482,100) (406,550)
Purchases of treasury stock (92,631) (158,884)
Proceeds from exercise of stock options 34,380 32,412
Capital stock surrendered to pay taxes on stock-based compensation (28,474) (27,548)
Dividends paid (19,788) (18,662)
Change in cash overdrafts payable (3,927) (1,531)
Payments on other long-term debt - (75,000)
Debt issuance costs - (1,052)
Other sources/(uses) 478 (938)
Net cash used by financing activities (109,162) (188,203)
Increase/(decrease) in Cash and Cash Equivalents 1,327 (6,290)
Cash and cash equivalents at beginning of year 4,831 11,121
Cash and cash equivalents at end of year $ 6,158 $ 4,831
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED DECEMBER 31, 2019 AND 2018
(in thousands)(unaudited)
Roto- Chemed
VITAS Rooter Corporate Consolidated
2019
Service revenues and sales (a) $ 339,905 $ 182,419 $ - $ 522,324
Cost of services provided and goods sold 253,659 93,696 - 347,355
Selling, general and administrative expenses (a) 21,162 46,198 15,931 83,291
Depreciation 5,341 5,747 38 11,126
Amortization 18 2,951 - 2,969
Other operating expense 25 106 - 131
Total costs and expenses 280,205 148,698 15,969 444,872
Income/(loss) from operations 59,700 33,721 (15,969) 77,452
Interest expense (19) (72) (1,042) (1,133)
Intercompany interest income/(expense) 4,740 1,543 (6,283) -
Other income net 76 40 3,160 3,276
Income/(loss) before income taxes 64,497 35,232 (20,134) 79,595
Income taxes (a) (15,075) (7,823) 8,883 (14,015)
Net income/(loss) $ 49,422 $ 27,409 $ (11,251) $ 65,580
2018
Service revenues and sales (b) $ 306,985 $ 150,522 $ - $ 457,507
Cost of services provided and goods sold 234,971 77,083 - 312,054
Selling, general and administrative expenses (b) 20,363 37,563 8,809 66,735
Depreciation 4,935 4,847 40 9,822
Amortization 12 291 - 303
Other operating expense 1,114 98 - 1,212
Total costs and expenses 261,395 119,882 8,849 390,126
Income/(loss) from operations 45,590 30,640 (8,849) 67,381
Interest expense (22) (64) (1,091) (1,177)
Intercompany interest income/(expense) 3,308 1,678 (4,986) -
Other income net 110 32 (3,540) (3,398)
Income/(loss) before income taxes 48,986 32,286 (18,466) 62,806
Income taxes (b) (9,860) (6,375) 7,757 (8,478)
Net income/(loss) $ 39,126 $ 25,911 $ (10,709) $ 54,328
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018
(in thousands)(unaudited)
Roto- Chemed
VITAS Rooter Corporate Consolidated
2019
Service revenues and sales (a) $ 1,281,184 $ 657,371 $ - $ 1,938,555
Cost of services provided and goods sold 982,056 339,070 - 1,321,126
Selling, general and administrative expenses (a) 86,345 166,934 52,433 305,712
Depreciation 19,984 20,730 156 40,870
Amortization 71 4,264 - 4,335
Other operating expense (a) 6,546 320 2,266 9,132
Total costs and expenses 1,095,002 531,318 54,855 1,681,175
Income/(loss) from operations 186,182 126,053 (54,855) 257,380
Interest expense (169) (345) (4,021) (4,535)
Intercompany interest income/(expense) 18,135 8,152 (26,287) -
Other income net 385 126 8,253 8,764
Income/(loss) before income taxes 204,533 133,986 (76,910) 261,609
Income taxes (a) (48,711) (30,276) 37,301 (41,686)
Net income/(loss) $ 155,822 $ 103,710 $ (39,609) $ 219,923
2018
Service revenues and sales (b) $ 1,197,562 $ 585,086 $ - $ 1,782,648
Cost of services provided and goods sold 928,306 299,338 - 1,227,644
Selling, general and administrative expenses (b) 81,969 145,683 43,557 271,209
Depreciation 19,688 18,629 147 38,464
Amortization 12 387 - 399
Other operating expense (b) 1,130 170 - 1,300
Total costs and expenses 1,031,105 464,207 43,704 1,539,016
Income/(loss) from operations 166,457 120,879 (43,704) 243,632
Interest expense (175) (319) (4,496) (4,990)
Intercompany interest income/(expense) 12,832 6,908 (19,740) -
Other income net 579 93 286 958
Income/(loss) before income taxes 179,693 127,561 (67,654) 239,600
Income taxes (b) (40,847) (28,850) 35,641 (34,056)
Net income/(loss) $ 138,846 $ 98,711 $ (32,013) $ 205,544
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THE THREE MONTHS ENDED DECEMBER 31, 2019 AND 2018
(in thousands)(unaudited)
Chemed
VITAS Roto-Rooter Corporate Consolidated
2019
Net income/(loss) $ 49,422 $ 27,409 $ (11,251) $ 65,580
Add/(deduct):
Interest expense 19 72 1,042 1,133
Income taxes 15,075 7,823 (8,883) 14,015
Depreciation 5,341 5,747 38 11,126
Amortization 18 2,951 - 2,969
EBITDA 69,875 44,002 (19,054) 94,823
Add/(deduct):
Intercompany interest expense/(income) (4,740) (1,543) 6,283 -
Interest income (84) (42) - (126)
Stock option expense - - 4,102 4,102
Long-term incentive compensation - - 3,079 3,079
Acquisition expense - 1,286 50 1,336
Medicare cap sequestration adjustment 919 - - 919
Adjusted EBITDA $ 65,970 $ 43,703 $ (5,540) $ 104,133
2018
Net income/(loss) $ 39,126 $ 25,911 $ (10,709) $ 54,328
Add/(deduct):
Interest expense 22 64 1,091 1,177
Income taxes 9,860 6,375 (7,757) 8,478
Depreciation 4,935 4,847 40 9,822
Amortization 12 291 - 303
EBITDA 53,955 37,488 (17,335) 74,108
Add/(deduct):
Intercompany interest expense/(income) (3,308) (1,678) 4,986 -
Interest income (111) (32) - (143)
Stock option expense - - 3,251 3,251
Long-term incentive compensation - - 2,242 2,242
Litigation settlement costs 1,000 - - 1,000
Medicare cap sequestration adjustment 456 - - 456
Acquisition expense 32 371 - 403
Adjusted EBITDA $ 52,024 $ 36,149 $ (6,856) $ 81,317
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018
(in thousands)(unaudited)
Chemed
VITAS Roto-Rooter Corporate Consolidated
2019
Net income/(loss) $ 155,822 $ 103,710 $ (39,609) $ 219,923
Add/(deduct):
Interest expense 169 345 4,021 4,535
Income taxes 48,711 30,276 (37,301) 41,686
Depreciation 19,984 20,730 156 40,870
Amortization 71 4,264 - 4,335
EBITDA 224,757 159,325 (72,733) 311,349
Add/(deduct):
Intercompany interest expense/(income) (18,135) (8,152) 26,287 -
Interest income (380) (133) - (513)
Stock option expense - - 14,831 14,831
Long-term incentive compensation - - 7,630 7,630
Litigation settlement 6,000 - - 6,000
Acquisition Expense - 4,664 170 4,834
Medicare cap sequestration adjustment 3,982 - - 3,982
Loss on sale of transportation equipment - - 2,266 2,266
Non cash ASC 842 expenses/(benefit) 656 55 (163) 548
Adjusted EBITDA $ 216,880 $ 155,759 $ (21,712) $ 350,927
2018
Net income/(loss) $ 138,846 $ 98,711 $ (32,013) $ 205,544
Add/(deduct):
Interest expense 175 319 4,496 4,990
Income taxes 40,847 28,850 (35,641) 34,056
Depreciation 19,688 18,629 147 38,464
Amortization 12 387 - 399
EBITDA 199,568 146,896 (63,011) 283,453
Add/(deduct):
Intercompany interest expense/(income) (12,832) (6,908) 19,740 -
Interest (income)/expense (580) (92) 1 (671)
Stock option expense - - 12,611 12,611
Long-term incentive compensation - - 6,618 6,618
Medicare cap sequestration adjustment 1,496 - - 1,496
Litigation settlement costs 796 - - 796
Acquisition expense 209 548 - 757
Amortization of stock awards 107 100 239 446
Adjusted EBITDA $ 188,764 $ 140,544 $ (23,802) $ 305,506
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)
Three Months Ended December 31, For the Years Ended December 31,
2019 2018 2019 2018
Net income as reported $ 65,580 $ 54,328 $ 219,923 $ 205,544
Add/(deduct) pre-tax cost of:
Stock option expense 4,102 3,251 14,831 12,611
Long-term incentive compensation 3,079 2,242 7,630 6,618
Litigation settlement - 1,000 6,000 796
Acquisition expense 1,336 403 4,834 757
Medicare cap sequestration adjustments 919 456 3,982 1,496
Amortization of acquired and cancelled franchise agreements 2,861 - 3,964 -
Loss on sale of transportation equipment - - 2,266 -
Non cash ASC 842 expenses - - 548 -
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1) (2,567) (1,527) (9,328) (4,586)
Excess tax benefits on stock compensation (5,440) (4,244) (24,177) (22,862)
Adjusted net income $ 69,870 $ 55,909 $ 230,473 $ 200,374
Diluted Earnings Per Share As Reported
Net income $ 3.96 $ 3.26 $ 13.31 $ 12.23
Average number of shares outstanding 16,565 16,670 16,527 16,803
Adjusted Diluted Earnings Per Share
Adjusted net income $ 4.22 $ 3.35 $ 13.95 $ 11.93
Average number of shares outstanding 16,565 16,670 16,527 16,803
(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
Three Months Ended December 31, For the Years Ended December31,
OPERATING STATISTICS 2019 2018 2019 2018
Net revenue ($000) (c)
Homecare $ 275,976 $ 261,972 $ 1,076,025 $ 1,010,518
Inpatient 30,857 20,874 99,920 82,677
Continuous care 40,997 30,834 133,473 122,498
Other 3,825 1,986 10,433 7,831
Subtotal $ 351,655 $ 315,666 $ 1,319,851 $ 1,223,524
Room and board, net (3,260) (2,191) (11,359) (10,054)
Contractual allowances (3,990) (3,036) (14,893) (11,785)
Medicare cap allowance (4,500) (3,454) (12,415) (4,123)
Net Revenue $ 339,905 $ 306,985 $ 1,281,184 $ 1,197,562
Net revenue as a percent of total before Medicare cap allowance
Homecare 78.5 % 83.0 % 81.5 % 82.6 %
Inpatient 8.8 6.6 7.6 6.8
Continuous care 11.7 9.8 10.1 10.0
Other 1.0 0.6 0.8 0.6
Subtotal 100.0 100.0 100.0 100.0
Room and board, net (0.9) (0.7) (0.9) (0.8)
Contractual allowances (1.1) (1.0) (1.1) (1.1)
Medicare cap allowance (1.3) (1.1) (0.9) (0.2)
Net Revenue 96.7 % 97.2 % 97.1 % 97.9 %
Average daily census ("ADC") (days)
Homecare 14,972 14,062 14,626 13,652
Nursing home 3,461 3,297 3,396 3,298
Routine homecare 18,433 17,359 18,022 16,950
Inpatient 375 326 366 327
Continuous care 450 464 458 465
Total 19,258 18,149 18,846 17,742
Total Admissions 17,479 16,579 69,859 68,119
Total Discharges 17,575 16,623 68,857 66,868
Average length of stay (days) 95.2 92.6 92.6 89.9
Median length of stay (days) 16.0 17.0 16.0 17.0
ADC by major diagnosis
Cerebro 35.8 % 35.8 % 36.0 % 36.3 %
Neurological 21.1 18.6 20.6 19.0
Cancer 12.8 13.7 12.9 13.7
Cardio 16.2 16.3 16.5 16.4
Respiratory 8.1 8.0 8.1 8.2
Other 6.0 7.6 5.9 6.4
Total 100.0 % 100.0 % 100.0 % 100.0 %
Admissions by major diagnosis
Cerebro 21.9 % 20.9 % 21.1 % 21.8 %
Neurological 12.9 11.5 12.6 11.4
Cancer 29.2 31.1 29.2 30.2
Cardio 14.7 14.6 15.5 15.4
Respiratory 10.5 10.1 11.0 10.9
Other 10.8 11.8 10.6 10.3
Total 100.0 % 100.0 % 100.0 % 100.0 %
Estimated uncollectible accounts as a percent of revenues 1.2 % 1.0 % 1.2 % 1.0 %
Accounts receivable --
Days of revenue outstanding- excluding unapplied Medicare payments 35.4 35.0 n.a. n.a.
Days of revenue outstanding- including unapplied Medicare payments 27.2 24.6 n.a. n.a.
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
FOOTNOTES TO FINANCIAL STATEMENTS
FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2019 AND 2018
(unaudited)
(a) Included in the results of operations for 2019 are the following significant credits/(charges) which may not be indicative of ongoing operations
(in thousands):
Three Months Ended December 31, 2019
VITAS Roto-Rooter Corporate Consolidated
Service revenues and sales:
Medicare cap sequestration adjustment $ (919) $ - $ - $ (919)
Selling, general and administrative expenses:
Stock option expense - - (4,102) (4,102)
Long-term incentive compensation - - (3,079) (3,079)
Amortization of acquired and cancelled franchise agreements - (2,861) - (2,861)
Acquisition expense - (1,286) (50) (1,336)
Pretax impact on earnings (919) (4,147) (7,231) (12,297)
Excess tax benefits on stock compensation - - 5,440 5,440
Income tax benefit on the above 233 1,101 1,233 2,567
After-tax impact on earnings $ (686) $ (3,046) $ (558) $ (4,290)
For the Year Ended December 31, 2019
VITAS Roto-Rooter Corporate Consolidated
Service revenues and sales:
Medicare cap sequestration adjustment $ (3,982) $ - $ - $ (3,982)
Selling, general and administrative expenses:
Stock option expense - - (14,831) (14,831)
Long-term incentive compensation - - (7,630) (7,630)
Acquisition expense - (4,664) (170) (4,834)
Amortization of acquired and cancelled franchise agreements - (3,964) - (3,964)
Non cash ASC 842 (expenses)/benefit (656) (55) 163 (548)
Other operating expenses:
Litigation settlement (6,000) - - (6,000)
Loss on sale of transportation equipment - - (2,266) (2,266)
Pretax impact on earnings (10,638) (8,683) (24,734) (44,055)
Excess tax benefits on stock compensation - - 24,177 24,177
Income tax benefit on the above 2,708 2,301 4,319 9,328
After-tax impact on earnings $ (7,930) $ (6,382) $ 3,762 $ (10,550)
(b) Included in the results of operations for 2018 are the following significant credits/(charges) which may not be indicative of ongoing operations
Three Months Ended December 31, 2018
VITAS Roto-Rooter Corporate Consolidated
Service revenues and sales:
Medicare cap sequestration adjustment $ (456) $ - $ - $ (456)
Selling, general and administrative expenses:
Stock option expense - - (3,251) (3,251)
Long-term incentive compensation - - (2,242) (2,242)
Acquisition expense (32) (371) - (403)
Other operating expenses:
Litigation settlement (1,000) - - (1,000)
Pretax impact on earnings (1,488) (371) (5,493) (7,352)
Excess tax benefits on stock compensation - - 4,244 4,244
Income tax benefit on the above 381 98 1,048 1,527
After-tax impact on earnings $ (1,107) $ (273) $ (201) $ (1,581)
For the Year Ended December 31, 2018
VITAS Roto-Rooter Corporate Consolidated
Service revenues and sales:
Medicare cap sequestration adjustment $ (1,496) $ - $ - $ (1,496)
Selling, general and administrative expenses:
Stock option expense - - (12,611) (12,611)
Long-term incentive compensation - - (6,618) (6,618)
Acquisition expense (209) (548) - (757)
Other operating expenses:
Litigation settlement (796) - - (796)
Pretax impact on earnings (2,501) (548) (19,229) (22,278)
Excess tax benefits on stock compensation - - 22,862 22,862
Income tax benefit on the above 637 145 3,804 4,586
After-tax impact on earnings $ (1,864) $ (403) $ 7,437 $ 5,170
VITAS has 12 large (greater than 450 ADC), 20 medium (greater than 200 but less than 450 ADC) and 16 small (less than 200 ADC) hospice programs. Of Vitas' 30 Medicare provider numbers,on a 12-month trailing basis, 23 provider numbers have a Medicare cap cushion of 10% or greater, three provider numbers have a cap cushion between 0% and 5%, and four provider numbers have a Medicare cap liability.
Last updated: Feb 18, 2020